|Home||» Products||» Inhaler||» Fluticasone Propionate Salmeterol Inhaler|
Expanded beta-agonists, such as one of the active constituents in fluticasone/salmeterol inhaler (salmeterol), have been seldom connected with an enhanced risk of asthma-related death. They may also promote the risk of asthma-attendant hospitalizations in children and adolescents. Fluticasone Propionate Salmeterol Inhaler should only be utilized to medicate asthma patients who are not controlled by the utilization of some other long-term asthma-control medications. The inhaler should not be used for the patients whose asthma can be cured by inhaled corticosteroids (eg, fluticasone). Fluticasone Propionate Salmeterol Inhaler is utilized for curing asthma in certain patients as well as to treat some other breathing states as suggested by your doctor.
The product is an inhaled corticosteroid and long-acting bronchodilator accumulation. The corticosteroid works by reducing excitation, and the bronchodilator works by expanding the airways in the lungs that assists the patients to breathe more easily.